EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp
Executive Summary
Two recently released studies could help Johnson & Johnson in its efforts to ward off competition for its anemia therapy Procrit (epoetin) from Amgen's second-generation erythropoietin product Aranesp (darbepoetin)
You may also be interested in...
Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer
Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer
Investors Judge Biotech Harshly: PDL BioPharma, MedImmune, Amgen Disappoint
Biotechnology investors could experience palpitations after this past quarter's dismal performance on the "The Pink Sheet" Index of NASDAQ stocks